Multiple System Atrophy (msa) Market Is Driven By Growing Awareness About Msa

By Author: colin
Total Articles: 166
Comment this article

Multiple system atrophy (MSA) is a rare neurodegenerative disorder characterized by poor control of voluntary movement, loss of ability to coordinate smooth and controlled muscle movements, and autonomic nervous system failure. The condition leads to a combination of parkinsonian, cerebellar, autonomic, and urogenital dysfunction. Some key symptoms of MSA include stiffness of muscles, poor balance and coordination, fainting or lightheadedness, incontinence, and trouble swallowing. Currently, there is no cure for MSA however diagnosis and management of symptoms can help improve quality of life for patients.

The Global MSA Market is estimated to be valued at US$ 137.3 Mn in 2024 and is expected to exhibit a CAGR of 4.4% over the forecast period 2024-2031.

Key Takeaways

Key players operating in the Multiple System Atrophy (MSA) are Chelsea Therapeutics International, Ltd., Biohaven Pharmaceuticals, Inc., Sumitomo Dainippon Pharma Co., Ltd., AstraZeneca plc, Theravance Biopharma, Inc. and Among Others. These players are involved in developing therapeutics for MSA treatment and management. Growing research support ...
... and funding from nonprofit organizations is also driving drug development efforts for MSA.

The growing demand for effective treatment options of MSA is another key factor driving the market. Currently, there are limited treatment approaches for MSA and available therapies only provide symptomatic relief. However, with ongoing research on novel targets, the demand for innovative drugs is increasing which is fueling market revenues.

The market is also witnessing expansion in terms of increased diagnosis rates globally. Initiatives to raise awareness about MSA among healthcare professionals and the general public are helping improve diagnosis capacity. Additionally, collaborations between industry and nonprofit organizations for expanding access to care in emerging markets will further support the growth of global MSA market over the coming years.

Market Drivers

The major market driver is the growing awareness about MSA. Efforts by nonprofit organizations in collaboration with researchers to educate people about symptoms and risk factors associated with MSA is helping improve diagnosis rates worldwide. As diagnosis levels increase, so does the demand for therapeutic drugs. Growing research support is also fueling a robust product pipeline which will drive market revenues once these drugs get approved. Increased patient assistance programs to boost access to care, especially in developing Asian and Latin American countries where MSA prevalence is high but diagnosis is low, will remain a key growth-inducing factor.

The current geopolitical situation is impacting the growth of the Multiple System Atrophy (MSA) market. The rising geopolitical tensions and conflicts between major nations are disrupting the global supply chains and logistics networks. This is making it challenging for biotech and pharmaceutical companies to supply their products and medications in a timely and cost-effective manner across borders. The delays in shipments and higher transport costs are hindering the distribution and affordability of MSA drugs in global markets.

The uncertainty arising from geopolitical issues is also causing delays and discontinuation of some clinical trials involving MSA drug candidates. Many biotech startups and small companies developing new MSA therapies are facing funding issues due to the volatility in stock markets driven by geopolitical risks. This is slowing down the drug innovation and development process for MSA. To counter these challenges, companies need to establish local manufacturing facilities and expand regional distribution networks. Diversifying supply sources and establishing collaborative partnerships can help mitigate geopolitical risks and their impact on business continuity and growth.

In terms of value, the North America region accounts for the largest share in the MSA market currently. This is due to favorable regulatory environment, availability of advanced healthcare facilities, and growing awareness about MSA in countries like the US and Canada. Europe is the second largest regional market supported by government funding for research on neurodegenerative disorders and presence of leading pharmaceutical companies.

The Asia Pacific region is expected to witness the fastest growth during the forecast period from 2024 to 2031. This is attributed to rising geriatric population, increasing healthcare spending, growing collaborations between local and international industry players in countries like China, India and Japan. Additionally, governments in Asia are investing heavily in developing local biotech capabilities, which will help boost clinical research on neurological conditions like MSA.

Get more insights on this topic: https://colinwilson11.hashnode.dev/rising-therapeutics-development-for-multiple-system-atrophy-will-drive-market-growth 

Author Bio

Vaagisha brings over three years of expertise as a content editor in the market research domain. Originally a creative writer, she discovered her passion for editing, combining her flair for writing with a meticulous eye for detail. Her ability to craft and refine compelling content makes her an invaluable asset in delivering polished and engaging write-ups. (LinkedIn: https://www.linkedin.com/in/vaagisha-singh-8080b91)

What Are The Key Data Covered In This Multiple System Atrophy (MSA) Market Report?

:- Market CAGR throughout the predicted period

:- Comprehensive information on the aspects that will drive the Multiple System Atrophy (MSA) 's growth between 2024 and 2031.

:- Accurate calculation of the size of the Multiple System Atrophy (MSA)  and its contribution to the market, with emphasis on the parent market

:- Realistic forecasts of future trends and changes in consumer behaviour

:- Multiple System Atrophy (MSA)  Industry Growth in North America, APAC, Europe, South America, the Middle East, and Africa

:- A complete examination of the market's competitive landscape, as well as extensive information on vendors

:- Detailed examination of the factors that will impede the expansion of Multiple System Atrophy (MSA)  vendors

FAQ’s

Q.1 What are the main factors influencing the Multiple System Atrophy (MSA) ?

Q.2 Which companies are the major sources in this industry?

Q.3 What are the market’s opportunities, risks, and general structure?

Q.4 Which of the top Multiple System Atrophy (MSA)  companies compare in terms of sales, revenue, and prices?

Q.5 Which businesses serve as the Multiple System Atrophy (MSA) ’s distributors, traders, and dealers?

Q.6 How are market types and applications and deals, revenue, and value explored?

Q.7 What does a business area’s assessment of agreements, income, and value implicate?

*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it